Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

<p>ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) — Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA I&T versus hormone therapy in patients with metastatic […]</p>
<p>The post <a href="https://forextv.com/top-news/curium-completes-patient-enrollment-of-phase-3-eclipse-trial-ahead-of-schedule/">Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>